Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid

Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid

Background. Patients afflicted with Alzheimer's disease (AD) exhibit a decrease in the cerebrospinal fluid (CSF) concentration of the 42 amino acid form of β-amyloid (Aβ42). However, a high discrepancy between different centers in measured Aβ42 levels reduces the utility of this biomarker as a...

Full description

Bibliographic Details
Main Authors: Maria Bjerke, Erik Portelius, Lennart Minthon, Anders Wallin, Henrik Anckarsäter, Rolf Anckarsäter, Niels Andreasen, Henrik Zetterberg, Ulf Andreasson, Kaj Blennow
Format: Article
Language:English
Published: Hindawi Limited 2010-01-01
Series:International Journal of Alzheimer's Disease
Online Access:http://dx.doi.org/10.4061/2010/986310
id doaj-ce095aa85bec4fbcbfd6b2e11763d2d0
record_format Article
spelling doaj-ce095aa85bec4fbcbfd6b2e11763d2d02020-11-24T20:44:03ZengHindawi LimitedInternational Journal of Alzheimer's Disease2090-02522010-01-01201010.4061/2010/986310986310Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal FluidMaria Bjerke0Erik Portelius1Lennart Minthon2Anders Wallin3Henrik Anckarsäter4Rolf Anckarsäter5Niels Andreasen6Henrik Zetterberg7Ulf Andreasson8Kaj Blennow9Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, 431 80 Mölndal, SwedenDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, 431 80 Mölndal, SwedenDepartment of Clinical Sciences Malmö, Clinical Memory Research Unit, Lund University, 205 02 Malmö, SwedenDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, 431 80 Mölndal, SwedenForensic Psychiatry, Institute of Neuroscience and Psychology, The Sahlgrenska Academy at University of Gothenburg, 422 50 Gothenburg, SwedenForensic Psychiatry, Institute of Neuroscience and Psychology, The Sahlgrenska Academy at University of Gothenburg, 422 50 Gothenburg, SwedenDepartment of Neurobiology, Karolinska Institute, Caring Sciences and Society, Karolinska University Hospital, Huddinge, 141 86 Stockholm, SwedenDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, 431 80 Mölndal, SwedenDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, 431 80 Mölndal, SwedenDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, 431 80 Mölndal, SwedenBackground. Patients afflicted with Alzheimer's disease (AD) exhibit a decrease in the cerebrospinal fluid (CSF) concentration of the 42 amino acid form of β-amyloid (Aβ42). However, a high discrepancy between different centers in measured Aβ42 levels reduces the utility of this biomarker as a diagnostic tool and in monitoring the effect of disease modifying drugs. Preanalytical and analytical confounding factors were examined with respect to their effect on the measured Aβ42 level. Methods. Aliquots of CSF samples were either treated differently prior to Aβ42 measurement or analyzed using different commercially available xMAP or ELISA assays. Results. Confounding factors affecting CSF Aβ42 levels were storage in different types of test tubes, dilution with detergent-containing buffer, plasma contamination, heat treatment, and the origin of the immunoassays used for quantification. Conclusion. In order to conduct multicenter studies, a standardized protocol to minimize preanalytical and analytical confounding factors is warranted.http://dx.doi.org/10.4061/2010/986310
collection DOAJ
language English
format Article
sources DOAJ
author Maria Bjerke
Erik Portelius
Lennart Minthon
Anders Wallin
Henrik Anckarsäter
Rolf Anckarsäter
Niels Andreasen
Henrik Zetterberg
Ulf Andreasson
Kaj Blennow
spellingShingle Maria Bjerke
Erik Portelius
Lennart Minthon
Anders Wallin
Henrik Anckarsäter
Rolf Anckarsäter
Niels Andreasen
Henrik Zetterberg
Ulf Andreasson
Kaj Blennow
Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid
International Journal of Alzheimer's Disease
author_facet Maria Bjerke
Erik Portelius
Lennart Minthon
Anders Wallin
Henrik Anckarsäter
Rolf Anckarsäter
Niels Andreasen
Henrik Zetterberg
Ulf Andreasson
Kaj Blennow
author_sort Maria Bjerke
title Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid
title_short Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid
title_full Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid
title_fullStr Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid
title_full_unstemmed Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid
title_sort confounding factors influencing amyloid beta concentration in cerebrospinal fluid
publisher Hindawi Limited
series International Journal of Alzheimer's Disease
issn 2090-0252
publishDate 2010-01-01
description Background. Patients afflicted with Alzheimer's disease (AD) exhibit a decrease in the cerebrospinal fluid (CSF) concentration of the 42 amino acid form of β-amyloid (Aβ42). However, a high discrepancy between different centers in measured Aβ42 levels reduces the utility of this biomarker as a diagnostic tool and in monitoring the effect of disease modifying drugs. Preanalytical and analytical confounding factors were examined with respect to their effect on the measured Aβ42 level. Methods. Aliquots of CSF samples were either treated differently prior to Aβ42 measurement or analyzed using different commercially available xMAP or ELISA assays. Results. Confounding factors affecting CSF Aβ42 levels were storage in different types of test tubes, dilution with detergent-containing buffer, plasma contamination, heat treatment, and the origin of the immunoassays used for quantification. Conclusion. In order to conduct multicenter studies, a standardized protocol to minimize preanalytical and analytical confounding factors is warranted.
url http://dx.doi.org/10.4061/2010/986310
work_keys_str_mv AT mariabjerke confoundingfactorsinfluencingamyloidbetaconcentrationincerebrospinalfluid
AT erikportelius confoundingfactorsinfluencingamyloidbetaconcentrationincerebrospinalfluid
AT lennartminthon confoundingfactorsinfluencingamyloidbetaconcentrationincerebrospinalfluid
AT anderswallin confoundingfactorsinfluencingamyloidbetaconcentrationincerebrospinalfluid
AT henrikanckarsater confoundingfactorsinfluencingamyloidbetaconcentrationincerebrospinalfluid
AT rolfanckarsater confoundingfactorsinfluencingamyloidbetaconcentrationincerebrospinalfluid
AT nielsandreasen confoundingfactorsinfluencingamyloidbetaconcentrationincerebrospinalfluid
AT henrikzetterberg confoundingfactorsinfluencingamyloidbetaconcentrationincerebrospinalfluid
AT ulfandreasson confoundingfactorsinfluencingamyloidbetaconcentrationincerebrospinalfluid
AT kajblennow confoundingfactorsinfluencingamyloidbetaconcentrationincerebrospinalfluid
_version_ 1716818542661206016

Similar Items